RecruitingPhase 2NCT06347653
Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)
Studying Nodal T-follicular helper cell lymphoma, follicular type
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peking University
- Principal Investigator
- PING WEI LIU, MasterPeking University Cancer Hospital & Institute
- Intervention
- linperlisib combined with CHOP regimen(drug)
- Enrollment
- 54 target
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2023 – 2030
Study locations (1)
- Bejing Cancer Hospital, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06347653 on ClinicalTrials.govOther trials for Nodal T-follicular helper cell lymphoma, follicular type
Additional recruiting or active studies for the same condition.
See all trials for Nodal T-follicular helper cell lymphoma, follicular type →